Phenylamino isonicotinamide compounds
The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation.
1. A method of inhibiting MEK activity in a subject suffering from a disease related to the hyperactivity of MEK or a disease modulated by the MEK cascade in mammals, comprising administering to a subject a compound of Formula (I)
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
X is NH or O,
R 1 is hydrogen, methyl, ethyl, n-propyl, i-propyl, SH or Hal,
R 2 is hydrogen, methoxy, ethoxy, acetylene, cyano, SH or Hal,
R 3 , R 4 are independently selected from hydrogen, SH or Hal,
R 5 , R 6 are independently selected from OH, SH or NH 2 and
Hal is F, Cl, Br or I.
2. A method of inhibiting MEK activity in a subject suffering from a disease related to the hyperactivity of MEK or a disease modulated by the MEK cascade in mammals, comprising administering to a subject a compound according to claim 1 in which radicals not designated in greater detail have the meaning indicated for the Formula (I) according to claim 1 but in which:
in Subformula IA
X is NH,
R 1 is Hal, methyl or ethyl,
R 2 is hydrogen, Hal, methoxy or acetylene,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula IB
X is NH,
R 1 is Hal,
R 2 is hydrogen or Hal,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula IC
X is NH,
R 1 is F, Cl, methyl or ethyl,
R 2 is hydrogen, I, Br, methoxy or acetylene,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula ID
X is NH,
R 1 is F, Cl, methyl or ethyl,
R 2 is hydrogen, I, Br, methoxy or acetylene,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl
R 5 , R 6 are OH,
in Subformula IE
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl
R 5 , R 6 are OH,
in Subformula IF
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl,
R 5 , R 6 are OH,
in Subformula IG
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen,
R 4 is hydrogen,
R 5 , R 6 are OH,
and in Subformula IH
X is NH,
R 1 is F,
R 2 is I,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl,
R 5 , R 6 are OH,
and pharmaceutically acceptable salts, solvates or prodrugs thereof.
3. A method of inhibiting MEK activity in a subject suffering from a disease related to the hyperactivity of MEK or a disease modulated by the MEK cascade in mammals, comprising administering to a subject the compound of Formula (II):
and pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein R 1 , R 2 , R 3 , and R 4 have the meaning indicated for Formula (I) or its subformulae IA, IB, IC, ID, IE, IF, IG or IH.
4. A method of inhibiting MEK activity in a subject suffering from a disease related to the hyperactivity of MEK or a disease modulated by the MEK cascade in mammals, comprising administering to a subject the compound according to Formula (I), wherein, the compound is selected from the group consisting of:
and pharmaceutically acceptable salts, solvates or prodrugs thereof.
5. The method of claim 1 , wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, haemangioma, glioma, melanoma and Kaposi's sarcoma.
6. The method of claim 2 , wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, haemangioma, glioma, melanoma and Kaposi's sarcoma.
7. The method of claim 3 , wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, haemangioma, glioma, melanoma and Kaposi's sarcoma.
8. The method of claim 4 , wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, haemangioma, glioma, melanoma and Kaposi's sarcoma.
9. The method of treating cancer as claimed in claim 5 , wherein the cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer, or melanoma, myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia or myeloid cell leukemia.
10. The method of treating cancer as claimed in claim 6 , wherein the cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer, or melanoma, myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia or myeloid cell leukemia.
11. The method of treating cancer as claimed in claim 7 , wherein the cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer, or melanoma, myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia or myeloid cell leukemia.
12. The method of treating cancer as claimed in claim 8 , wherein the cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer, or melanoma, myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia or myeloid cell leukemia.
13. A method for treating cancer selected from the group consisting of colon cancer, melanoma and pancreatic cancer related to the hyperactivity of MEK in mammals, comprising administering to a subject a compound of Formula (I)
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
X is NH or O,
R 1 is hydrogen, methyl, ethyl, n-propyl, i-propyl, SH or Hal,
R 2 is hydrogen, methoxy, ethoxy, acetylene, cyano, SH or Hal,
R 3 , R 4 are independently selected from hydrogen, SH or Hal,
R 5 , R 6 are independently selected from OH, SH or NH 2 and
Hal is F, Cl, Br or I.
14. A method for treating cancer selected from the group consisting of colon cancer, melanoma and pancreatic cancer related to the hyperactivity of MEK in mammals, comprising administering to a subject a compound according to claim 13 in which radicals not designated in greater detail have the meaning indicated for the Formula (I) according to claim 13 but in which:
in Subformula IA
X is NH,
R 1 is Hal, methyl or ethyl,
R 2 is hydrogen, Hal, methoxy or acetylene,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula IB
X is NH,
R 1 is Hal,
R 2 is hydrogen or Hal,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula IC
X is NH,
R 1 is F, Cl, methyl or ethyl,
R 2 is hydrogen, I, Br, methoxy or acetylene,
R 3 is hydrogen or Hal,
R 4 is hydrogen or Hal,
R 5 , R 6 are OH,
Hal is F, Cl, Br or I,
in Subformula ID
X is NH,
R 1 is F, Cl, methyl or ethyl,
R 2 is hydrogen, I, Br, methoxy or acetylene,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl
R 5 , R 6 are OH,
in Subformula IE
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl
R 5 , R 6 are OH,
in Subformula IF
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl,
R 5 , R 6 are OH,
in Subformula IG
X is NH,
R 1 is F or Cl,
R 2 is I or Br,
R 3 is hydrogen,
R 4 is hydrogen,
R 5 , R 6 are OH,
and in Subformula IH
X is NH,
R 1 is F,
R 2 is I,
R 3 is hydrogen or F,
R 4 is hydrogen or Cl,
R 5 , R 6 are OH,
and pharmaceutically acceptable salts, solvates or prodrugs thereof.